Gamco Investors INC. ET AL lowered its position in Henry Schein Inc (NASDAQ:HSIC) by 7.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 255,559 shares of the company’s stock after selling 20,069 shares during the quarter. Gamco Investors INC. ET AL’s holdings in Henry Schein were worth $17,176,000 at the end of the most recent quarter.
Several other hedge funds have also recently made changes to their positions in the company. Captrust Financial Advisors purchased a new stake in Henry Schein during the 4th quarter worth about $141,000. Advisory Services Network LLC increased its position in Henry Schein by 430.1% during the 4th quarter. Advisory Services Network LLC now owns 2,099 shares of the company’s stock worth $147,000 after purchasing an additional 1,703 shares in the last quarter. Fuller & Thaler Asset Management Inc. increased its position in Henry Schein by 100.0% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 2,400 shares of the company’s stock worth $168,000 after purchasing an additional 1,200 shares in the last quarter. Ford Financial Group Inc. purchased a new stake in Henry Schein during the 4th quarter worth about $182,000. Finally, Cetera Advisor Networks LLC purchased a new stake in Henry Schein during the 4th quarter worth about $210,000. Institutional investors and hedge funds own 95.58% of the company’s stock.
HSIC has been the subject of a number of recent research reports. TheStreet upgraded Henry Schein from a “c” rating to a “b-” rating in a research report on Monday, May 14th. Zacks Investment Research raised Henry Schein from a “hold” rating to a “buy” rating and set a $83.00 price target on the stock in a research note on Tuesday, April 24th. Deutsche Bank raised their price target on Henry Schein from $79.00 to $82.00 and gave the stock a “buy” rating in a research note on Tuesday, April 24th. Northcoast Research set a $102.00 price target on Henry Schein and gave the stock a “buy” rating in a research note on Tuesday, April 24th. Finally, Barclays began coverage on Henry Schein in a research note on Thursday, March 8th. They issued an “equal weight” rating and a $71.00 price target on the stock. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $81.59.
NASDAQ HSIC opened at $70.43 on Friday. The stock has a market capitalization of $10.88 billion, a PE ratio of 19.56, a PEG ratio of 1.69 and a beta of 1.04. Henry Schein Inc has a 1-year low of $62.56 and a 1-year high of $93.50. The company has a current ratio of 1.44, a quick ratio of 0.74 and a debt-to-equity ratio of 0.34.
Henry Schein (NASDAQ:HSIC) last released its quarterly earnings data on Tuesday, May 8th. The company reported $0.95 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.03. The business had revenue of $3.22 billion for the quarter, compared to analyst estimates of $3.18 billion. Henry Schein had a return on equity of 19.68% and a net margin of 3.18%. The company’s revenue was up 10.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.88 EPS. sell-side analysts expect that Henry Schein Inc will post 4.1 EPS for the current fiscal year.
Henry Schein Company Profile
Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, animal health clinics, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein Inc (NASDAQ:HSIC).
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.